Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children

Insights

Timing morning insulin injections for diabetic children impacts post-breakfast blood sugar. An early injection 30 minutes before breakfast resulted in lower glucose levels compared to a late injection 5 minutes prior.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Insulin-dependent diabetics often experience a post-breakfast hyperglycaemic peak.
  • Optimizing insulin timing is crucial for managing blood glucose levels in children with diabetes.

Purpose of the Study:

  • To investigate the effect of varying morning mixed insulin injection timing on postprandial hyperglycaemia in diabetic children.
  • To assess the impact of early versus late insulin administration before breakfast on glucose control.

Main Methods:

  • A randomized crossover study involving nine diabetic children at home.
  • Comparison of insulin injections administered 30 minutes (early) versus 5 minutes (late) before breakfast.
  • Serial blood sampling and analysis of glucose, insulin, C-peptide, pyruvate, lactate, alanine, and ketones over 3.5 hours.

Main Results:

  • The early injection regimen consistently resulted in lower blood glucose concentrations compared to the late injection regimen.
  • A significant difference in blood glucose levels was observed at 150 minutes post-injection.
  • Plasma insulin levels were higher with the early regimen after 0 minutes, indicating improved insulin availability during the post-breakfast period.

Conclusions:

  • The timing of morning insulin injections significantly influences postprandial hyperglycaemia control in diabetic children.
  • Administering mixed insulin (Monotard and Actrapid) 30 minutes before breakfast is more effective than a 5-minute pre-breakfast injection.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...